Benny Amore
Amgen (United States)(US)Esperion Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Liver physiology and pathology, Cancer Research and Treatments, Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors(2017)205 cited
- → Influence of Molecular Flexibility and Polar Surface Area Metrics on Oral Bioavailability in the Rat(2004)165 cited
- → Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.(2015)109 cited
- → Predicting Drug Absorption: How Nature Made It a Difficult Problem(2002)102 cited
- → Teratogenicity of carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouse.(1996)55 cited
- → Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors(2018)55 cited
- → In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models(2016)54 cited
- → PROTEIN-REACTIVE METABOLITES OF CARBAMAZEPINE IN MOUSE LIVER MICROSOMES(1996)54 cited
- → First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3Kδ, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies(2013)40 cited
- → Effect of treatment with phenobarbital and stiripentol on carbamazepine‐induced teratogenicity and reactive metabolite formation(1995)37 cited